|
|
||||||||
Mary Beth Flynn Makic is a researcher nurse scientist for critical care and an assistant professor at the University of Colorado, Denver.
Elizabeth Bridges is the clinical nurse researcher at the University of Washington Medical Center in Seattle and an assistant professor at the University of Washington School of Nursing in Seattle. She is also a colonel in the US Air Force Reserve assigned to the 60th Medical Group at Travis Air Force Base, California.
To purchase electronic or print reprints, contact The InnoVision Group, 101 Columbia, Aliso Viejo, CA 92656. Phone, (800) 899-1712 or (949) 362-2050 (ext 532); fax, (949) 362-2049; e-mail, reprints{at}aacn.org.
To learn more about fluid replacement, read "Weaning Readiness and Fluid Balance in Older Critically Ill Surgical Patients" by Carol Diane Epstein and Joel R. Peerless in the American Journal of Critical Care, 2006;15(1):54–64. Available at www.ajcconline.org.
Now that youve read the article, create or contribute to an online discussion about this topic using eLetters. Just visit www.ccnonline.org and click "Respond to This Article" in either the full-text or PDF view of the article.
None reported.
Corresponding author: Carol A. Rauen, RN, MS, CCNS, CCRN, PCCN, 104 Queen Mary Court, Kill Devil Hills, NC 27948 (e-mail: carol.rauen{at}charter.net).
This article is a published report of a 2008 session at the National Teaching Institute and is the second report from that annual session on evidence-based practice. We focus on 4 areas common to everyday critical care practice. Elizabeth Bridges addresses positioning of patients for monitoring hemodynamic parameters. Mary Beth Flynn Makic discusses 2 topics: (1) whether low-dose dopamine prevents or can be used to prevent or treat renal dysfunction and (2) prevention of deep vein thrombosis. Carol A. Rauen describes the facts and physiology of fluid replacement. The clinical questions and current body of evidence that can assist clinicians in moving research to bedside practice are reviewed and recommendations are outlined.
Positioning Patients for Hemodynamic Monitoring
One challenge critical care nurses face is how to answer the question, does my patient need to lie flat for hemodynamic monitoring? In order to address this challenge, a series of questions must be answered: (1) What is the correct reference level for a given position? (2) Are studies in a given population of patients (eg, patients with heart failure, acute respiratory distress syndrome [ARDS], sepsis, cardiac surgery) available that describe the differences in hemodynamic parameters in the supine vs back-rest elevated position or supine vs lateral or prone position? (3) Are the observed differences in pulmonary artery pressure (PAP) and central venous pressure (CVP) with the patient in the flat and supine position compared with an alternative position greater than the spontaneous variability in pressure? An exciting aspect of the evidence to answer these questions is that most research on positioning of patients for monitoring hemodynamic parameters has been conducted by nurse researchers.
Position-Specific Reference Level
Regardless of a patients body position, the key to accurate measurements of hemodynamic parameters is the use of a position-specific reference level to correct for hydrostatic pressure (Table 1
, Figure 1
). By convention, the phlebostatic axis is the reference point for the right and left atria.4,5,7,10 The phlebostatic axis is defined as the intersection of 2 reference lines: first, an imaginary line from the fourth intercostal space at the point where the space joins the sternum, drawn out to the side of the body; second, a line drawn midway between the anterior and posterior surfaces of the chest.11 The phlebostatic level is a horizontal line through the phlebostatic axis. The air-fluid interface of the stopcock of the transducer must be level with this axis for accurate measurements. In patients with a normal chest wall configuration, the midaxillary line is a valid reference level for the right and left atria; however, use of the midaxillary line in patients with a different chest configuration may result in a pressure difference of up to 6 mm Hg.12 An alternative reference point is 5 cm below the angle of the sternum. This reference point reflects the middle of the right atrium and remains the same up to 60º back-rest elevation.13 Use of this alternative reference point, which is also recommended for evaluation of jugular venous distention, results in a CVP measurement that is 3 mm Hg lower than a CVP measured from a system referenced to the phlebostatic axis.13,14 In the lateral position, reference points have been validated for the 30º and 90º lateral positions with a 0º backrest elevation5–7,15 (Table 1
). In studies6,16–22 done to evaluate the effects of a prone position on hemodynamic parameters, the midaxillary line or the midanteroposterior diameter of the chest has been used as the reference point, although the accuracy of this reference has not been validated. The reference point should be marked on the patients chest, and the air-fluid interface of the system should be leveled by using a laser or carpenters level and not the "eyeball" method.23
|
|
Supine, Trendelenburg/Reverse Trendelenburg.
Hemodynamic measurements should not be obtained with patients in the Trendelenburg position. Although PAP and CVP increase when patients are in the Trendelenburg position, neither intrathoracic blood volume (preload) nor cardiac function increases.35 No research has been done on the effect of the common practice of elevating the head of the bed and then placing the entire bed in the Trendelenburg position to prevent the patient from sliding down in the bed. Also, no research has been done to directly evaluate the effect of use of the reverse Trendelenburg position on PAP and CVP. However, compared with the supine position, a 15º passive tilt decreases cardiac output by 10%, and a 45º tilt decreases cardiac output by approximately 20%.36 This research36 suggests that patients legs should be parallel to the ground while hemodynamic measurements are being obtained.
Lateral Position.
Results of early studies37–43 showed significant differences in PAP and CVP when measured with the patient in the lateral position (20º–90º) rather than flat and supine. However, in these studies, the phlebostatic axis or the midsternum was generally used as the reference point. These reference points, which are not accurate during lateral rotation, introduced measurement error into the results.44 For example, in the 30º lateral position, use of the midsternum rather than the validated angle-specific reference6 would introduce an error of approximately 7 mm Hg. In contrast, in 2 studies,45,46 in which the validated reference point was used, investigators found no clinically significant changes in CVP and PAP in most trauma patients45 and patients who had undergone cardiac surgery.46 In the cardiac surgery patients, the supine and lateral measurements of pulmonary artery occlusion pressure differed by less than 2 mm Hg,44 a finding that most likely reflects the 80- to 460-mL position-induced increase in cardiac output.47 If the effects of the incorrect reference point were corrected, these original studies would on average have results similar to the results of studies that used the angle-specific reference.46 In addition, in cardiac and medical-surgical ICU patients, PAP and CVP measured in patients in the 90º position were similar to measurements obtained with the patients supine, as long as the correct angle-specific reference was used.15,40 No studies in which the correct angle-specific reference was used have been completed in patients with severe lung disease or in a combined lateral position with the head of the bed elevated.
Prone Position.
Patients may be placed prone as a part of therapy for ARDS or during surgical procedures. In patients with acute lung injury or ARDS, if adequate time (30–60 minutes) is allowed for stabilization after repositioning, no clinically significant differences in PAP, CVP, or cardiac output are apparent16–22 (Table 2
). However, in patients with normal pulmonary function, such as those undergoing spinal surgery, cardiac index may be slightly lower when the patient is prone.48–50 Questions to ask include whether abdominal compression in the prone position increases intra-abdominal pressure, and if so, does the increased intra-abdominal pressure affect the accuracy of the PAP and CVP measurements. As demonstrated in Table 3
, in patients with normal intra-abdominal pressure, prone positioning does not significantly increase intra-abdominal pressure or intrathoracic blood volume and does not falsely increase CVP.17,18 However, the effect of the prone position on hemodynamic parameters in patients with intra-abdominal hypertension (intra-abdominal pressure>12 mm Hg) is not known, an important situation because intra-abdominal hypertension occurs in up to 50% of ICU patients.51 Additionally, no studies have been done in patients in automated proning beds (eg, Rotoprone), and studies are needed to describe the effects that combined prone positioning with lateral rotation with the bed flat and the prone/reverse Trendelenburg position have on hemodynamic parameters.
|
|
Finally, evidence on the effect of position on hemodynamic parameters must be interpreted cautiously. Although on average, hemodynamic parameters do not differ significantly with patients in the various positions, individual patients may respond to a given position in different ways. Thus, it is imperative to systematically assess each patients hemodynamic response in a given position before assuming that the measurement will not differ from measurements obtained with the patient supine and flat57,58 (Figure 2
). The evidence-based recommendations related to monitoring hemodynamic parameters for various body positions are summarized in Table 4
.
|
|
Use of low-dose dopamine, or renal dose dopamine, has become a widely accepted clinical practice for preventing or treating renal dysfunction.59 Does this agent truly protect the kidneys from acute dysfunction? The evidence does not support the use of low-dose dopamine to prevent or treat renal dysfunction. In fact, multiple studies59–63 have shown no evidence that dopamine prevents renal dysfunction or provides renal protection, and the agent may even be harmful for patients.
Dopamine is a drug with diverse effects at multiple receptor sites in the body; this endogenous cate-cholamine regulates cardiac, vascular, and endocrine function. Dopamine is a complex agent; the response to it depends on which receptors in the body are stimulated (Table 5
). Conventional dosing of dopamine suggests that low dosages (0.5–3.0 µg/kg per minute) stimulate dopaminergic receptors and result in coronary and renal vasodilatation, natriuresis, and diuresis. Midrange dosing (3–8 µg/kg per minute) activates β-adrenergic receptors, increasing cardiac inotropy and chronotropy. Dosages greater than 8 µg/kg per minute predominantly stimulate
-adrenergic receptors, resulting in splanchnic and peripheral vasoconstriction.64–67 This conventional dosing is inaccurate. Research suggests that dopamine infusions at similar infusion rates produce different responses from patient to patient.66 One explanation of the variation in responses is that the activation of the receptor sites depends more on the patient than on the dose; thus the concept of dose range affecting specific receptors is not universal for all patients.66,67 As a result, traditional dopamine dosing should not be used as a standard regimen. The desired effects of dopamine infusion depend on the specific patients response to the agent.59,64,66,67
|
In a report published in 1999, Marik and Iglesias63 concluded that giving low-dose dopamine to patients with septic shock and oliguria did not lead to any significant differences in the incidence of acute renal failure, need for dialysis, or 28-day survival. Then Kellum and Decker59 did a meta-analysis of the use of dopamine in acute renal failure. They concluded that the use of low-dose dopamine to treat or prevent acute renal failure cannot be justified on the basis of available evidence and should be eliminated from critical care protocols.59
Despite this evidence, the ongoing clinical use of low-dose dopamine continued. Friedrich et al62 published a meta-analysis and evidence-based review on low-dose dopamine, concluding that after 15 years of research on the effectiveness of renal dose dopamine, the evidence indicates that low-dose dopamine temporarily improves renal output but does not prevent renal dysfunction or death. Thus, the evidence is conclusive: use of low-dose dopamine does not prevent or improve renal dysfunction long-term in critically ill patients.59,60,62,64–66 These findings should not be confused with results of studies that examined the effectiveness of higher doses of dopamine in critically ill patients with heart failure and septic shock. In such patients, dopamine is beneficial for its inotropic and vasoactive properties.60,65
So why does urine output increase when a dopamine infusion is started? Dopamine has both natriuretic and diuretic properties that stimulate urine output, and the response appears to be more pronounced at lower dosages.64,66,67 This response, however, is often temporary, and urine output tapers off within the first 24 hours.62 Dopamine at doses as low as 2 µg/kg per minute improves cardiac output and mean arterial pressure, enhancing renal perfusion and urine output.66–68 Concerns about the use of low-dose dopamine extend beyond the evidence that the drug is not effective in preventing renal dysfunction.
Current evidence suggests low-dose dopamine may cause harm by worsening splanchnic oxygen consumption, impairing gastric motility, inducing tachyarrhythmias (especially in elderly patients), and blunting ventilatory response to hypercarbia.61,69,70 Administration of dopamine should be continually evaluated to match the dose to the desired outcome without causing adverse consequences for the patient.
Does renal dose dopamine exist? No, it does not. Dopamine does not protect the kidneys from renal dysfunction.59,61,63
Prevention of Deep Vein Thrombosis: What Is Best?
Venous thromboembolism is the combined term that describes both deep vein thrombosis (DVT) and pulmonary embolism. Recent estimates suggest that venous thromboembolism is diagnosed in more than 900 000 patients in the United States annually, with approximately 400 000 cases manifested as DVT and 500 000 cases as pulmonary embolism. In 60% of the patients with pulmonary embolism, the embolism is fatal.71,72 Patients in whom venous thromboembolism develops are also at risk for post-thrombotic syndrome, in which tissue injury follows DVT and lasts indefinitely, causing damage of venous valves, pain, paresthesia, hyperpigmentation, pruritus, venous dilatation, edema, and ulceration.73,74 Research findings71,75 indicate that clinical interventions, including mechanical and pharmacological therapies, are effective in preventing venous thromboembolism; however, only approximately one-third of all patients at risk for venous thromboembolism receive prophylactic therapy. The most common reasons cited for lack of proper prophylaxis of venous thromboembolism include lack of knowledge among providers, underestimation of patients risk for venous thromboembolism, and overestimation of the potential risk of bleeding associated with prophylaxis.74–77
Prevention of venous thromboembolism is considered a clear opportunity for improving safe care of patients.77 Several national organizations and accrediting bodies list the prevention of venous thromboembolism as a patient safety indicator and measure of quality of care or "never events."71,78 In 2003, The American Public Health Association published guidelines to advance public awareness of DVT.76 Geerts et al75 published evidence-based guidelines for the prevention of venous thromboembolism, and that seminal article was followed in 2008 with practice guidelines for antithrombotic therapy for venous thromboembolism.79 Evidence is available to guide practice for providing interventions to prevent venous thromboembolism. The challenge is to use this evidence in the daily practice of critical care nursing.
Prevention of venous thromboembolism begins with assessment of a patients risk factors. A venous thromboembolism is an intravascular fibrin clot that usually forms in regions of slow or disturbed blood flow. Typically the clot forms in a large vein in the lower extremities, but it may form in any large vein and poses a great risk when it occludes a pulmonary vessel, potentially resulting in a fatal pulmonary embolism. Classic risk factors for ICU patients are well known by nurses. The variables are referred to as the Virchow triad: venous stasis or obstruction, blood vessel injury, and increased coagulability. Frequent procedures disrupt a patients vessels, and the fluid shifts, immobility, and coagulation disorders associated with critical illness place ICU patients at high risk for venous thromboembolism. DVT develops in up to 30% of ICU patients within the first week of admission, a characteristic that further emphasizes the importance of early interventions.80 To decrease the prevalence of venous thromboembolism, critical care nurses must evaluate each patients risk and implement preventative interventions when the patient is admitted to the unit.
Additional risk factors beyond venous stasis, immobility, and vascular injury should be included in the assessment of each patients risk for venous thromboembolism. Risk factors can be grouped in many ways to include patient-specific variables, type of procedure a patient is undergoing (eg, orthopedic surgery), and reason for admission (eg, traumatic event; Table 6
). Top risk factors include prolonged immobility, including use of neuromuscular blockade and/or heavy sedation; an indwelling central venous catheter; major surgery; cancer; active infection; pregnancy; hormone therapy; obesity; respiratory failure; heart failure; cerebral vascular accident; trauma (especially fractures of the pelvis, hip, or leg); history of previous venous thromboembolism; and older age (ie, risk increases in patients 40 years or older).75,81 The more risk factors a patient has, the more aggressive the interventions should be.
|
Pharmacological prevention consists of unfractionated heparin, low-molecular-weight heparin, fondaparinux, and vitamin K antagonists (eg, warfarin). Many variables must be assessed before pharmacological interventions are started, including the risk for venous thromboembolism, presence of bleeding, and desired duration of therapy. As a patients risk increases, more aggressive pharmacological therapy combined with mechanical interventions is required. Low-molecular-weight heparin is often prescribed because the evidence suggests that this agent is as effective as unfractionated heparin in preventing DVT, has fewer adverse effects (eg, bleeding, heparin-induced thrombocy-topenia) and better bioavailability, and is safe in the outpatient setting, allowing for long-term therapy as needed.79,87 High-risk patients may require more aggressive treatment with low-molecular-weight heparin, fondaparinux, or warfarin. The evidence on aspirin is well established: aspirin alone is not effective in preventing DVT.75 The 2008 guidelines of the American College of Chest Physicians79 provide a full review of the evidence supporting antithrombotic therapy.
What are the best procedures for preventing DVT? First and foremost, preventive interventions must be implemented consistently for all critically ill patients to effectively decrease the incidence of venous thromboembolism. Second, patients should be assessed for severity of risk on the basis of age, medical and surgical history, and projected course of the critical illness. Third, each patients plan of care should be reviewed and pharmacological therapy that may help reduce the risk for venous thromboembolism should be discussed. Fourth, mechanical devices must be correctly fitted and consistently applied for effective preventative therapy. Finally, when possible, patients should ambulate (Table 7
). Although all venous thromboembolism may not be preventable in critically ill patients, the evidence indicates that its occurrence can be reduced, and nurses owe it to patients to base practice on the best evidence to minimize the risk for venous thromboembolism.
|
Fluid replacement has long been a cornerstone of critical care practice. Historically, the question was not whether a patient needed fluids but what type of fluid would be best. Now the physiological value of administering fluids is being questioned. The goal in fluid replacement is clear: maintain adequate intravascular volume to ensure cellular oxygen delivery and cardiac output. The means to achieve that goal, however, is much more complex.
Both crystalloids and colloids have significant advantages and disadvantages. Crystalloids, which include normal saline and lactated Ringer solutions, are isotonic, inexpensive, readily available, good volume expanders that are easy to store and administer. These fluids do not transmit diseases or cause allergic reactions, and both can replace some electrolytes. However, normal saline and lactated Ringer solutions do not have oxygen-carrying capacity, and approximately 75% of the fluid administered leaks into the interstitial space within hours of administration. Large volumes of these fluids can lead to pulmonary edema and, because the blood components are diluted, can actually lead to more bleeding.88 The natural and synthetic blood products (colloids) are much better volume expanders than crystalloids are and, because of their molecular size, tend to stay in the intravascular space longer. Colloids not only stay in that space, but because of their protein components, they actually can set up an osmotic gradient that will "pull" plasma from the interstitium into the intravascular space. These fluids are more expensive, are more difficult to store and administer, often require cross-matching, might transmit diseases or microorganisms, and might lead to an allergic or inflammatory response.
Albumin may have many of the advantages of natural colloids without the disadvantages of crystalloids. Finfer et al89 found no significant differences between patients given saline and patients given albumin in the number of days in the ICU or hospital or in the number of days that mechanical ventilation or renal-replacement therapy was required.
Dubois et al90 studied a mixed population of medical-surgical ICU patients and found that albumin might even have an advantage over normal saline: organ function was improved and tube feedings were more readily tolerated in the patients who received albumin rather than saline.
Human blood products remain the best fluid for patients who have lost blood or have symptomatic anemia, but large volumes of blood are not without risk. The potential complications of using blood products include coagulation disorders, metabolic derangements, infection, sepsis, anaphylaxis, and disease transmission.91–94 Since the late 1990s, administration of blood has also been implicated in transfusion-related acute lung injury, transfusion-associated circulatory overload, and transfusion-related immune modulation.91–94 The question of what fluid is best has no risk-free answer.95
Human blood products are also the fluid of choice for patients with symptomatic bleeding whose blood pressure cannot be increased with crystalloid administration and whose bleeding has not been controlled.91 The gold standard for treating such patients has been fluids and lots of them. However, administering crystalloids to such patients can actually cause more bleeding. The increase in intravascular volume should increase blood pressure. If the bleeding source is arterial, the increase in blood pressure could actually disrupt clotting and lead to more bleeding.
Crystalloids dilute clotting factors and platelet volumes. The current recommendation for suspected arterial bleeding is to delay fluid replacement until surgery to control the bleeding is under way.95 It is widely believed that warm fluid is better than cold. Being cold lowers the core temperature and makes coagulopathies worse. The question remains: what should the end-point parameters be for fluid replacement?
The issue of how much fluid to administer or when to stop is a difficult one. Vincent and Weil96 question the traditional clinical parameters that have been used for decades. Historically, fluids were cut back when CVP increased. If the goal is intravascular fluid replacement, it must be remembered that CVP reflects only the pressure in the central veins. It does not represent total vascular volume. The same could be said for pulmonary edema. Fluid could be leaking into the lung interstitial spaces because of the high hydrostatic pressure in the pulmonary capillary bed or because of the low oncotic pressure and left ventricular failure. Tachycardia is often used as an indicator of anemia or dehydration, but Vincent and Weil point out that it is not a particularly sensitive measure. Tachycardia is a warning sign for many problems in critical care.
In a study of early goal-directed therapy, Rivers et al97 attempted to answer the question of replacement end points. Emergency department patients in septic shock had better outcomes when they had early goal-directed replacement with the following end points:
CVP: 8 to 12 cm H2O
Mean arterial pressure: greater than 65 mm Hg
Urine output: greater than 0.5 mL/kg per hour
Central venous oxygen saturation: 70%
These parameters were part of the Surviving Sepsis Campaign guidelines in 2004 and were recommended a second time in the 2008 guidelines.98,99 The other recommendations in the 2008 guidelines include fluid replacement with 300 to 500 mL of colloids or 1 L of crystalloids in 30 minutes and reducing the fluid challenge rate if filling pressures increase without improvement in hemodynamic status.99
How much blood is the right amount of blood has also been researched. The first hemoglobin trigger that was recommended dates back to Adam and Lundy100 in 1942. The "10/30" rule was used in clinical practice for more than 4 decades. If a patients hemoglobin level decreased to less than 10 g/dL or the hematocrit decreased to less than 0.30, the patient was given blood. The discovery that human immunodeficiency virus was transmitted via blood and the expanding knowledge of the risks of blood administration have led clinicians to reevaluate the risks and benefits of administering blood and to search for a better trigger threshold. The report of the current landmark study,92 published in 1999, included recommendations that hemoglobin level be maintained between 7 and 9 g/dL. The 2004 and 2008 Surviving Sepsis Campaign guidelines included this recommendation.98,99 The standard exceptions to the trigger value of 7 to 9 g/dL are patients with ischemic heart disease and patients who have had an acute myocardial infarction. Corwin et al91 reported that, despite the commonly known risks of blood administration and the new recommendations, clinical practice in the United States did not change much between 1999 and 2003. In a 2008 analysis of data on blood transfusions included in the Sepsis Occurrence in Acutely Ill Patients data base, Vincent et al94 found that administration of blood was associated with improved mortality. More randomized controlled studies are needed in critically ill patients to answer these age-old questions of which solution, how much, and when best to deliver fluids to critically ill patients.
In the absence of specific evidence-based practice guidelines for fluid replacement in critically ill patients, "For the present, the choice is best made contingent on the underlying disease, the type of fluid that has been lost, the severity of circulatory failure, the serum albumin concentration of the patient and the risk of bleeding."96(p1336) The short answer to the simple question of fluid replacement is that no perfect solution exists. Patients should be given what they lost or what they need that will cause the least harm. Nurses must continue to conduct research to find a better answer.95
Summary
This article is the second article published in Critical Care Nurse that outlines evidence-based practices that should be applied at the bedside. The challenge before us is 3-fold: we must continue to ask the hard clinical questions, conduct the research to answer these questions, and implement the discoveries that are made. This final challenge is probably the most difficult. We fear that in todays environment of cost cutting and staffing shortages, uncritical adherence to tradition will become the norm again. We must create a culture of inquiry and practice changes based on research and implement new standards that are based on the latest available evidence.
PRIME POINTS
Acknowledgments
The authors served as an expert panel on evidence-based practice at the 2008 National Teaching Institute in Chicago, Illinois. We thank the American Association of Critical-Care Nurses, Linda Bell, Nancy Munro, and the entire Advance Practice Work Group for their insight in pulling the panel together to present this information at the 2008 National Teaching Institute.
References
This article has been cited by other articles:
![]() |
G. Alspach Handing Off Critically Ill Patients to Family Caregivers: What Are Your Best Practices? Crit. Care Nurse, June 1, 2009; 29(3): 12 - 22. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |